Fireman B.V. (IFRX) Stock Price, Quote & News

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa,...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 3641 508 180

Website: www.inflarx.de

Address:

Winzerlaer Str. 2, Jena, Germany

createrrit Dec. 19 at 10:09 PM

$IFRX @dogDazeSummer nothing more cowardly than blocking somebody and then posting behind their backs, thinking they wouldn’t be able to read it, lol You didn’t refute my point of the company going alone on HS, at least until we hear otherwise, based on this post (which kinda makes sense, based on their history). Your ‘contributions” over the year, were nothing but constant pumping and speculation, have some self respect, man.

1 · Reply

dogDazeSummer Dec. 19 at 9:51 PM

$IFRX I do my best to contribute & invest in relationships that allow information to flow to this board. Most appreciate, but some enjoy a “sport game” of putdowns. Sadly, this is the case after going back to look at a profile —-he’s rarely adding valuable information to the collective group. For those reasons @createrrit is a block. I’ll continue to help people who respect what’s involved in maintaining rapport, respectful dialogue, and the cost cost of maintaining multiple analyst relationships. Pressing out good vibes to all.

0 · Reply

dogDazeSummer Dec. 19 at 7:20 PM

$IFRX Although disappointing in the share price, could we have a few January surprises up sleeve? The company chose to avoid dilution of $1 offering. Send a thank you note to them for not totally screwing existing shareholders over —-while they were persuaded to by the vultures. Some speculate they *couldnt* do funding-regardless of couldnt or wouldn’t - it’s a “Diamond in The Ruff” at $85M fully diluted valuation. Many have taken their losses and moved on - and announced the decisions here. Better to liquidate today for 10% more than earlier in week if it doesn’t make sense to see what Q1 brings? Meanwhile, does the dwindling % of retail investors recognize similar patterns from w/b: 8/25 vs 12/15? Reminders on what Niels did / didn’t do 5 years ago lack relevancy.

2 · Reply

redistributeW Dec. 19 at 6:59 PM

$IFRX Yummy picking up fomo

0 · Reply

redistributeW Dec. 19 at 5:00 PM

$IFRX weak volume

0 · Reply

MrCompassion Dec. 19 at 4:12 PM

$IFRX A surge of interest it seems in study of complement within neuroimmunology, the link between the immune system and the nervous system, this paper detailing particular interest in what happens within cells: “The discovery of this intracellular system represents a significant paradigm shift. It reframes complement from a purely extracellular immune surveillance cascade to a fundamental intracellular regulator. This ‘complosome’ provides a direct mechanistic link between innate immunity and core cellular processes, such as metabolic status and survival decisions.” A complex system, not to be toyed with to desired effect. Keyword *control* in controlling inflammation. Step aside cytokine blockers and JAK/BTK breakers of immune function, not of common sense health care. “This complexity underscores that broad C5a/C5aR1 inhibition, while beneficial in some chronic inflammatory contexts, may inadvertently block essential repair mechanisms. Future therapies may need to

1 · Reply

cielo1 Dec. 19 at 2:58 PM

$IFRX if IFRX was a submarine they would be the best in the world for controlled silence! Are those iS dotted and ts crossed yet!? All the best to all!!! Mega

1 · Reply

dogDazeSummer Dec. 19 at 1:56 PM

Friday Buyouts Continue with $FOLD being taken out by $BMRN Congrats to all, I owned 125 shares! What a catalyst rich year 2025 has been. $IFRX has been awfully quiet since the stunning data release in Nov and voluntarily chose not to do an offering…hmmmm https://finance.yahoo.com/news/biomarin-pharmaceutical-acquire-amicus-therapeutics-133314206.html

1 · Reply

dogDazeSummer Dec. 19 at 1:43 AM

@createrrit No offense at all taken - sharing bc most ppl on ST don’t get access to sell side research. Always be aware: “Caution when feeding the seagulls” - but also $IFRX is the smallest market cap in entire 80 page report on “gem list” —some $1B+ I doubt Guggenheim is really “making bank” off our $30M Feb offering that didn’t have an over allotment. Yes, they were lead underwriter - but this report is KOL based & obv rewards entities who bank w them. Nobody is crushing it on Inflarx - not Mgt base salaries, not shareholders, not analysts, not brokerage firms, nor patients…Yet. Otherwise - why wld it be “a hidden gem” by definition? Let’s hope —-let’s pray —that Gugg and their expansive team of KOLs (who most firms wouldn’t spend $ to put on payroll) make $50M- 500M in underwriting fees. God bless !! If anyone deserves underwriting fees, both Cantor (via Seedhouse). aka $RJF and Gugg are winners imo. Watch for some $JPM mid Jan +/-, DYOD

1 · Reply

GTMStox Dec. 19 at 1:06 AM

$IFRX Sold out of this POS today. This company doesn't deserve my investment. GL to all longs.

3 · Reply

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

Nov 10, 2025, 2:41 PM EST - 5 weeks ago

InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript

Nov 10, 2025, 7:30 AM EST - 5 weeks ago

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

Nov 7, 2025, 4:05 PM EST - 6 weeks ago

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Oct 21, 2025, 7:20 AM EDT - 2 months ago

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Sep 12, 2025, 8:30 AM EDT - 3 months ago

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 21, 2025, 7:30 AM EDT - 4 months ago

InflaRx Announces Participation in September Investor Conferences

Aug 7, 2025, 7:30 AM EDT - 4 months ago

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:30 AM EDT - 5 months ago

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Jul 11, 2025, 4:15 PM EDT - 5 months ago

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

May 28, 2025, 11:00 AM EDT - 7 months ago

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

May 28, 2025, 1:30 AM EDT - 7 months ago

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 22, 2025, 7:30 AM EDT - 7 months ago

InflaRx to Participate in Upcoming Investor Conferences

May 7, 2025, 7:30 AM EDT - 8 months ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 8 months ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Mar 20, 2025, 7:30 AM EDT - 9 months ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 7, 2025, 8:00 AM EST - 10 months ago

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025, 9:00 AM EST - 10 months ago

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 25, 2025, 7:30 AM EST - 10 months ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 18, 2025, 4:01 PM EST - 10 months ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 9:45 PM EST - 11 months ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 4:01 PM EST - 11 months ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 23, 2025, 7:30 AM EST - 11 months ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 15, 2025, 12:30 PM EST - 1 year ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Dec 20, 2024, 7:30 AM EST - 1 year ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Nov 15, 2024, 7:51 AM EST - 1 year ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 8, 2024, 7:30 AM EST - 1 year ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 25, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 3, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 27, 2024, 7:30 AM EDT - 1 year ago

InflaRx Announces Participation in September Investor Events

Aug 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Jun 24, 2024, 8:02 AM EDT - 1 year ago

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 5, 2024, 12:00 PM EDT - 1 year ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

May 21, 2024, 2:30 PM EDT - 1 year ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

Mar 21, 2024, 7:00 AM EDT - 1 year ago

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

Mar 19, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Feb 22, 2024, 7:30 AM EST - 1 year ago

InflaRx Appoints Jan Medina as Head of Investor Relations

Jan 25, 2024, 7:30 AM EST - 2 years ago

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Jan 4, 2024, 7:00 AM EST - 2 years ago

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Nov 6, 2023, 7:30 AM EST - 2 years ago

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Nov 1, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Sep 11, 2023, 7:00 AM EDT - 2 years ago

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Sep 6, 2023, 5:31 PM EDT - 2 years ago

InflaRx: Small German Company Targeting A Rare Indication

Aug 30, 2023, 7:30 AM EDT - 2 years ago

InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Aug 10, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

Jun 28, 2023, 7:30 AM EDT - 2 years ago

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Jun 21, 2023, 7:00 AM EDT - 2 years ago

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

createrrit Dec. 19 at 10:09 PM

1 · Reply

dogDazeSummer Dec. 19 at 9:51 PM

0 · Reply

dogDazeSummer Dec. 19 at 7:20 PM

2 · Reply

redistributeW Dec. 19 at 6:59 PM

$IFRX Yummy picking up fomo

0 · Reply

redistributeW Dec. 19 at 5:00 PM

$IFRX weak volume

0 · Reply

MrCompassion Dec. 19 at 4:12 PM

1 · Reply

cielo1 Dec. 19 at 2:58 PM

$IFRX if IFRX was a submarine they would be the best in the world for controlled silence! Are those iS dotted and ts crossed yet!? All the best to all!!! Mega

1 · Reply

dogDazeSummer Dec. 19 at 1:56 PM

1 · Reply

dogDazeSummer Dec. 19 at 1:43 AM

1 · Reply

GTMStox Dec. 19 at 1:06 AM

$IFRX Sold out of this POS today. This company doesn't deserve my investment. GL to all longs.

3 · Reply

dogDazeSummer Dec. 18 at 8:56 PM

$IFRX Part 2 Hidden Gems according to Guggenheim (don’t shooot messanger): “….where AMGN’s avacopan could limited therapeutic window. IFRX has recently announced positive topline results from the Phase IIa 4-week basket study: (1) In HS, Izicopan demonstrated rapid & compelling efficacy that are aligned with successful biologic comparators, with clear safety and a dose-dependent profile; (2) In CSU, while the efficacy signal is stronger in HS,‘904 drives reduction in UAS7 within a range indicative of clinical activity. Given there is no other development in the oral C5aR space, IFRX could inaugurate a new MoA across this multibillion dollar indication market. Initiation of a Phase II program for Izicopan…. Also mentioned as hidden gems: $RAPT $PHAT $SION $FBRX

1 · Reply

dogDazeSummer Dec. 18 at 8:11 PM

$IFRX Guggenheim Just Out….. 2026 Preview of Immunological Hidden Gems Investors Probably Aren’t Folllowing…. “We believe IFRX's oral C5aR inhibitor, Izicopan (prev. INF-904), could be significant source of value for the company. Izicopan has the potential to be a better version of $AMGN Tavneos (avacopan) and IFRX could adopt a fast follower approach and develop it across a number of autoimmune indications where AMGN’s avacopan could not be developed due to a limited therapeutic window…..DATA……” …continued. More to follow…. 1 of 5 names listed under “hidden gems” Also: $ACET $ALMS $CABA

1 · Reply

cielo1 Dec. 18 at 7:13 PM

$IFRX An announcement of a seasoned CEO taking the helm would get us to at least $5 with no other news, so many options at mgmt disposal, as others have said the pipeline is majorly de-risked with all the past history. Let's see!

1 · Reply

dogDazeSummer Dec. 18 at 5:07 PM

$IFRX Watch for double bottom formation (early vs mid December) amid tax loss selling. They’ve tried to take below on 2 occasions, both unsuccessful thus far. Coming off a catalyst rich 2025, we now have a de-risked asset with Izicopan that works in CSU & HS. If you think BP cares about ‘time to revenue’ more than a SAFE / ORAL ‘revenue generator’, you might be mistaken. An easy double from current prices after retail throws in the towel, amid obvious & expected exhaustion (given time). $JPM biggest annual event & good to see the company continue to focus on partnerships, funding, BD, how quickly we forget $BIIB $AMGN like the space and paid 10-50x to be in it. Their respective buys are pre clinical and the latter has liver tox side effects. #See5 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash

1 · Reply

Monkey82 Dec. 18 at 4:29 PM

$IFRX There is a great deal of disappointment with the company for various reasons, as shown by the comments on this board especially over the past few weeks. While it may seem dire, let’s keep in mind that we have a winner in izicopan from the P2a trial especially in HS and arguably in CSU too. Both markets are $1B+ each. A partnership or buyout is the next logical step. Either option will not be achieved overnight. I agree time is of the essence and Q1 is critical for the company and investors alike. We will have an outcome that while perhaps below our expectations will at least give us the funding and time necessary to conduct izicopan P2b studies. The stock deserves to be higher of course but past trial failure overhang, fear of dilution including the ATM or an offering, as well as a lack of cooperation from NIH for vilo have all contributed to the current market situation. We should hold on for the next 8-12 weeks - and see what materializes in terms of funding announcement.

1 · Reply

MrCompassion Dec. 18 at 3:36 PM

$IFRX At least we can always appreciate the foundational science behind InflaRx biotech. Interesting Cleveland Clinic paper. “Central to this progress is a deeper appreciation of the complement system, a key component of innate immunity, and its role in neuroinflammation…Over the past decade, complement-related therapeutic advances, including those targeting central components such as C3 and C5 or specific pathways, have transformed the clinical landscape for many immune-mediated neurological disorder diseases.” https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1695461/full

2 · Reply

cielo1 Dec. 18 at 1:31 PM

$IFRX ok is it time? Let's finally see that buyout. Niels et al ,you gave it your best now let's see experts take the lead!

2 · Reply

redistributeW Dec. 18 at 12:51 PM

$IFRX Several people seemed to be concerned about the stock dilution. All biotechnology companies have an unending thirst and needs to raise cash for clinical trials,research and development. I'm just not seeing an overly abusive excessive dilution here. The outstanding shares are relatively low. The problem here is results. GSK just announced a collaboration with Camp4 They turned around and haan offering.

1 · Reply

GMSinvest Dec. 18 at 5:00 AM

$IFRX remember when mister blocked anyone who disagreed with him? Who’s the fool now?

1 · Reply

MrCompassion Dec. 17 at 10:28 PM

$IFRX I’ll forever share the Prof R-esque enthusiasm for this biotech, will always have deep respect for the vision the company founders had in starting this company. My critique however (of late) is about tangibles. Why did you invest in IFRX? Promise of Gohibic sales? I invested in the wider promise of Vilo, this now spotlighted (attempted anyway) INF904 product an interesting but years-out hope at best. $7 million invested in hopes of what? Which catalyst and associated timeline are we talking about? PG topline? Gohibic sales? EU progress? Trickle 904 p2a data? Partnership? Selling of the farm? PG was a deathblow to this already down and out company. Insulting to shareholders to suggest failure had to do with site recruitment blunders. With no big picture plan post probable endpoint miss, this waste of time and resources study only served to solidify market impression of InflaRx, of its inability to run successful studies. Can’t convince the

4 · Reply

Monkey82 Dec. 17 at 9:16 PM

$IFRX Coal in my Christmas stocking this year??

1 · Reply

GMSinvest Dec. 17 at 2:56 PM

$IFRX if not €5 by early April, vote against all board recommendations and force a proxy vote at AGM. As you wish, Niels

3 · Reply

Market Cap	67.80M
Revenue (ttm)	180,000.00
Net Income (ttm)	-49.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27,694.44%
Debt to Equity Ratio	0.00

Volume	808,800
Avg Vol	3,514,306
Day's Range	N/A - N/A
Shares Out	67.13M
Stochastic %K	76%
Beta	1.46
Analysts	Strong Sell
Price Target	$9.00